News & Media
News & Media

News & Media

The latest on Curie Therapeutics
Curie Therapeutics Appoints Georgette Verdin as Chief People Officer
Curie Therapeutics Appoints Georgette Verdin as Chief People Officer

CAMBRIDGE, Mass., March 14th, 2022 — Curie Therapeutics Inc. (“Curie”), a biotechnology company focused on developing innovative radiopharmaceutical therapies for oncological diseases, today announced the appointment of Georgette Verdin as the Company’s Chief People Officer. “Our people are central to achieving our vision of transforming the use of radiopharmaceuticals in oncology. We are invested in…

03/08/22
Curie Therapeutics Appoints Karen Smith, M.D., Ph.D., as Independent Board Director
02/07/22
Curie Therapeutics Expands Radiopharmaceutical Expertise with Appointment of Bernard Lambert, Ph.D. as Chief Technology Officer
02/03/22
Curie Therapeutics Appoints Kapil Dhingra, MBBS, to Board of Directors
12/01/21
Curie Therapeutics Raises $75 Million Financing to Further its Mission of Transforming Cancer Care with Precision Radiopharmaceuticals

Contact Us

Curie Therapeutics Inc.
2F Gill Street
Woburn MA 01801

For Media:
sarah@argotpartners.com

For Investors:
kevin@argotpartners.com